<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Y</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1025-1035</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12657239</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>647(8091)</volume><pubmed_abstract>Chronic infections and cancer cause T cell dysfunction known as exhaustion. This cell state is caused by persistent antigen exposure, suboptimal co-stimulation and a plethora of hostile factors that dampen protective immunity and limit the efficacy of immunotherapies&lt;sup>1-4&lt;/sup>. The mechanisms that underlie T cell exhaustion remain poorly understood. Here we analyse the proteome of CD8&lt;sup>+&lt;/sup> exhausted T (T&lt;sub>ex&lt;/sub>) cells across multiple states of exhaustion in the context of both chronic viral infections and cancer. We show that there is a non-stochastic pathway-specific discordance between mRNA and protein dynamics between T effector (T&lt;sub>eff&lt;/sub>) and T&lt;sub>ex&lt;/sub> cells. We identify a distinct proteotoxic stress response (PSR) in T&lt;sub>ex&lt;/sub> cells, which we term T&lt;sub>ex&lt;/sub>-PSR. Contrary to canonical stress responses that induce a reduction in protein synthesis&lt;sup>5,6&lt;/sup>, T&lt;sub>ex&lt;/sub>-PSR involves an increase in global translation activity and an upregulation of specialized chaperone proteins. T&lt;sub>ex&lt;/sub>-PSR is further characterized by the accumulation of protein aggregates and stress granules and an increase in autophagy-dominant protein catabolism. We establish that disruption of proteostasis alone can convert T&lt;sub>eff&lt;/sub> cells to T&lt;sub>ex&lt;/sub> cells, and we link T&lt;sub>ex&lt;/sub>-PSR mechanistically to persistent AKT signalling. Finally, disruption of T&lt;sub>ex&lt;/sub>-PSR-associated chaperones in CD8&lt;sup>+&lt;/sup> T cells improves cancer immunotherapy in preclinical models. Moreover, a high T&lt;sub>ex&lt;/sub>-PSR in T cells from patients with cancer confers poor responses to clinical immunotherapy. Collectively, our findings indicate that T&lt;sub>ex&lt;/sub>-PSR is a hallmark and a mechanistic driver of T cell exhaustion, which raises the possibility of targeting proteostasis pathways as an approach for cancer immunotherapy.</pubmed_abstract><journal>Nature</journal><pubmed_title>Proteotoxic stress response drives T cell exhaustion and immune evasion.</pubmed_title><pmcid>PMC12657239</pmcid><funding_grant_id>R01 CA282501</funding_grant_id><funding_grant_id>R35 GM150723</funding_grant_id><funding_grant_id>R01 AI170926</funding_grant_id><funding_grant_id>R01 CA262069</funding_grant_id><funding_grant_id>R21 CA267394</funding_grant_id><pubmed_authors>Abdel-Hakeem MS</pubmed_authors><pubmed_authors>Song NJ</pubmed_authors><pubmed_authors>Wen H</pubmed_authors><pubmed_authors>Huang SC</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Shannon AE</pubmed_authors><pubmed_authors>Mandula JK</pubmed_authors><pubmed_authors>Ghoneim HE</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Yousif A</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Wu W</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Xiao T</pubmed_authors><pubmed_authors>Xin G</pubmed_authors><pubmed_authors>Ghosh G</pubmed_authors><pubmed_authors>Searle BC</pubmed_authors><pubmed_authors>Velegraki M</pubmed_authors><pubmed_authors>Beusch CM</pubmed_authors><pubmed_authors>Ma A</pubmed_authors><pubmed_authors>Dawood AS</pubmed_authors><pubmed_authors>Saadey AA</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Amankwah YS</pubmed_authors><pubmed_authors>Gordon DE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Proteotoxic stress response drives T cell exhaustion and immune evasion.</name><description>Chronic infections and cancer cause T cell dysfunction known as exhaustion. This cell state is caused by persistent antigen exposure, suboptimal co-stimulation and a plethora of hostile factors that dampen protective immunity and limit the efficacy of immunotherapies&lt;sup>1-4&lt;/sup>. The mechanisms that underlie T cell exhaustion remain poorly understood. Here we analyse the proteome of CD8&lt;sup>+&lt;/sup> exhausted T (T&lt;sub>ex&lt;/sub>) cells across multiple states of exhaustion in the context of both chronic viral infections and cancer. We show that there is a non-stochastic pathway-specific discordance between mRNA and protein dynamics between T effector (T&lt;sub>eff&lt;/sub>) and T&lt;sub>ex&lt;/sub> cells. We identify a distinct proteotoxic stress response (PSR) in T&lt;sub>ex&lt;/sub> cells, which we term T&lt;sub>ex&lt;/sub>-PSR. Contrary to canonical stress responses that induce a reduction in protein synthesis&lt;sup>5,6&lt;/sup>, T&lt;sub>ex&lt;/sub>-PSR involves an increase in global translation activity and an upregulation of specialized chaperone proteins. T&lt;sub>ex&lt;/sub>-PSR is further characterized by the accumulation of protein aggregates and stress granules and an increase in autophagy-dominant protein catabolism. We establish that disruption of proteostasis alone can convert T&lt;sub>eff&lt;/sub> cells to T&lt;sub>ex&lt;/sub> cells, and we link T&lt;sub>ex&lt;/sub>-PSR mechanistically to persistent AKT signalling. Finally, disruption of T&lt;sub>ex&lt;/sub>-PSR-associated chaperones in CD8&lt;sup>+&lt;/sup> T cells improves cancer immunotherapy in preclinical models. Moreover, a high T&lt;sub>ex&lt;/sub>-PSR in T cells from patients with cancer confers poor responses to clinical immunotherapy. Collectively, our findings indicate that T&lt;sub>ex&lt;/sub>-PSR is a hallmark and a mechanistic driver of T cell exhaustion, which raises the possibility of targeting proteostasis pathways as an approach for cancer immunotherapy.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-06T15:44:08.204Z</modification><creation>2026-06-02T03:09:18.557Z</creation></dates><accession>S-EPMC12657239</accession><cross_references><pubmed>41034580</pubmed><doi>10.1038/s41586-025-09539-1</doi></cross_references></HashMap>